Inogen stock: buy or sell?
August 22nd, 2019
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally.
Should I buy Inogen stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Inogen stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Inogen stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 10 ratings published for INGN stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-8||Svb Leerink||Outperform||Market Perform|
|2019-8-8||Leerink Swann||Outperform||Market Perform|
|2019-8-7||Needham & Company LLC||Buy||Hold|
|2019-7-3||JPMorgan Chase & Co.||Neutral||Underweight|
|2019-6-28||Needham & Company LLC||Strong-Buy||Buy|
|2019-5-8||JPMorgan Chase & Co.||Overweight||Neutral|
|2019-4-9||Needham & Company LLC||n/a||Buy|
|2019-2-27||Piper Jaffray Companies||n/a||Overweight|
|2019-2-27||Needham & Company LLC||Strong-Buy||Strong-Buy|
|2019-2-27||JPMorgan Chase & Co.||Positive||Overweight|
Inogen stock analysis
Inogen shares soared 3.30% to $44.72 today.
Shares of Inogen soared a brilliant 3.30% and closed at $44.72. INGN is soaring again after a 12.55% correction from its last top on August/9 at $47.49.
After sliding a chilling -6.54% in a week last week, Inogen closed this week at $44.72 and boosted a super good 6.02%.
Since early November 2018, when INGN stock price broke down the 40-weeks moving avarage line, it slid $-149.58 per share (-76.98%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support. Far behind is the all-time high Inogen hit by mid September 2018 and since then the price is -84.46% below that top.
Inogen stock price history
Inogen IPO was on February 14th, 2014 at $16.00 per share1. Since then, INGN stock grew a 179.50%, with a yearly average of 35.90%. If you had invested right after INGN's IPO a $1,000 in Inogen stock in 2014, it would worth $1,795.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Inogen stock historical price chart
INGN stock reached all-time highs on September with a price of $287.79.
Inogen stock price target is $128.00How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 8 price targets for INGN stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-3||JPMorgan Chase & Co.||Downgrades||n/a||$72.00||-|
|2019-6-28||Needham & Company LLC||Downgrades||$111.00||$91.00||-18%|
|2019-5-8||JPMorgan Chase & Co.||Downgrades||$175.00||$72.00||-58.9%|
|2019-4-9||Needham & Company LLC||Reiterates||n/a||$191.00||-|
|2019-2-27||Piper Jaffray Companies||Lowers Target||$290.00||$185.00||-36.2%|
|2019-2-27||Needham & Company LLC||Reiterates||$280.00||$191.00||-31.8%|
|2019-2-27||JPMorgan Chase & Co.||Lowers Target||n/a||$175.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Inogen reported its latest financial data, posting a dazzling gain for the Earnings per Share (EPS) ratio. Analyst expected $0.25 per share, but Inogen posted $0.44.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Inogen annual turnover boosted an exceptional 43.57% to $358.11 million dollars from $249.44 marked in 2017. Instead, its profit margin (compared to sales) soared to 14.48%, that is $51.85 million.
|2013||$75 M||-||$25 M33.7%||-|
|2014||$113 M||49.17%||$6.83 M6.1%||-73.17%|
|2015||$159 M||41.29%||$12 M7.3%||69.72%|
|2016||$203 M||27.56%||$21 M10.1%||77.12%|
|2017||$249 M||22.98%||$21 M8.4%||2.35%|
|2018||$358 M||43.57%||$52 M14.5%||146.86%|
Quarterly financial resultsInogen reported $86.53 M in sales for 2018-Q4, a -9.19% less compared to previous quarter. Reported quarter earnings marked $10.05 million with a profit margin of 11.61%. Profit margin dropped a -5.64% compared to previous quarter when profit margin was 17.24%. When comparing revenues to same quarter last year, Inogen sales marked a super good gain and skyrocketed a 35.66%. Looking back to recent quarterly results, Inogen posted 2 negative quarters in a row.
|2017-Q1||$53 M||-||$6 M11.3%||-|
|2017-Q2||$64 M||22.13%||$8 M13.0%||40.64%|
|2017-Q3||$69 M||7.66%||$7 M10.6%||-12.01%|
|2017-Q4||$64 M||-7.60%||$-1 M-1.0%||-108.26%|
|2018-Q1||$79 M||23.93%||$11 M13.6%||-1,875.25%|
|2018-Q2||$97 M||23.01%||$15 M15.0%||35.81%|
|2018-Q3||$95 M||-2.00%||$16 M17.2%||12.47%|
|2018-Q4||$87 M||-9.19%||$10 M11.6%||-38.87%|
Inogen ownershipWhen you are planning to buy shares of a company, it's worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Inogen, 1.17% of all outstanding shares are owned by its staff.
Bearish positions for INGN stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Inogen:
|Market cap||$980.7 M||$6.1 M||$44.7 M||$2.0 B||$174.2 M|
|Total shares||21.9 M||4.0 M||8.4 M||31.7 M||33.8 M|
|Float shares||18.2 M||3.4 M||6.8 M||33.9 M||32.8 M|
|- Institutional holdings (%)||109.7%||11.2%||25.9%||106.7%||124.2%|
|- Insider holdings (%)||1.2%||62.9%||18.5%||6.3%||3.5%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Thursday, August 22nd, 2019|
|Day range||$42.84 - $45.05|
|Average true range||$3.36|
|50d mov avg||$59.01|
|100d mov avg||$68.27|
|200d mov avg||$98.97|
Inogen performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared Inogen against Allied Healthcare Products, Electromed, Chart Industries, Invacare, Masimo, Koninklijke Philips, ResMed and XTL Biopharmaceuticals in the following table: